Cipla Completes Phase-3 Clinical Study Of A Billion-Dollar Asthma Generic
Cipla Ltd. said it successfully completed the clinical endpoint study evaluating the safety and efficacy of a generic of Glaxo SmithKline Plc.'s respiratory drug Advair Diskus.
The Phase-3 clinical trial for fluticasone propionate and salmeterol inhalation powder (100/50 mcg)—successfully completed in the first attempt—was conducted over a period of 15 months at more than 100 sites in the U.S. enrolling 1,400 asthma patients, the Mumbai-based drugmaker said in an exchange filing.
The product is indicated to treat asthma in patients four years and older as a twice-daily prescription medicine and in long term to treat chronic obstructive pulmonary, including chronic bronchitis, emphysema, or both, for better breathing and fewer flare-ups disease, it said.
Advair Diskus and its generic equivalents, according to pharma researcher IMS Health, had U.S. sales of about $2.9 billion for the 12-month period ending February 2020.
Emkay analyst Praful Bohra said being a complex product and based on past experience of other players, it was highly likely that the approval pathway for Cipla will be longer than the usual one-year cycle.
But if approved, Cipla's copy-cat version will be the fourth such drug after innovator GSK and authorised generics of Prasco and Mylan. U.K.-based Hikma Pharmaceuticals has guided for a launch in the second half of calendar year 2020, while Germany's Sandoz discontinued the drug's development.
Credit Suisse said although Cipla might receive an approval after two to three years, it was an important drug, given the large size of the market and the company being the fourth generic. Advair Diskus, the brokerage said, can add 10 percent to Cipla's earnings per share in the first year of launch.
According to Investec, with complexity around development and the high capital outlay, this is a big opportunity for Cipla, which can generate revenue of $100 million annually after launch. Cipla is in with a realistic chance of launching the product in calendar year 2022, and a timely launch could boost Cipla's FY23 earnings and possibly FY22 depending on approval, Anshuman Gupta, analyst at the brokerage said in a note.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.